President Joe Biden (Susan Walsh/AP Images)

Up­dat­ed: US se­lects first 10 drugs sub­ject to Medicare price ne­go­ti­a­tions

The US on Tues­day un­veiled the first 10 drugs that will be sub­ject to price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act, in­clud­ing sev­er­al sur­pris­ing ad­di­tions that may face com­pe­ti­tion from gener­ics be­fore the ne­go­ti­a­tions start in 2026.

In to­tal, the drugs racked up more than $50 bil­lion in Medicare Part D spend­ing from May 2022 to June of this year, and in­clude three prod­ucts from John­son & John­son as well as block­busters from Bris­tol My­ers Squibb, Eli Lil­ly, Mer­ck and oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.